News
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness.
Center for Biologics Evaluation and Research (CBER) has suspended the biologics license for Valneva’s Ixchiq (Chikungunya ...
HealthDay News — The US Food and Drug Administration (FDA) is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports ...
The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker ...
U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...
The United States Food and Drug Administration (FDA) has suspended the licence of one of the two chikungunya vaccines ...
MedPage Today on MSN23h
In Abrupt Reversal, FDA Yanks Ixchiq Vaccine Over Safety Concern
According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...
Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...
Health and Me on MSN14h
Chikungunya Vaccine License Suspended In U.S. By FDA
The U.S. FDA has suspended the license for Valneva’s chikungunya vaccine Ixchiq after reports of severe side effects, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback